Other content in this Stream
Prometic to host key opinion leader meeting on PBI-4050, a novel treatment for Alström Syndrome
Key Opinion Leader meeting, Friday, September 7th in New York City, on a novel treatment for Alström Syndrome (AS).
Prometic announces the publication of PBI-4050’s antifibrotic activity in liver diseases in journal of pharmacology
n the ongoing Phase 2 clinical trial in patients with Alström syndrome, PBI-4050 was shown to significantly reduce liver and cardiac fibrosis.
Prometic receives rare pediatric disease designation from U.S. FDA for small molecule drug candidate PBI-4050
In addition to the Rare Pediatric Disease Designation, PBI-4050 was previously granted Orphan Drug Designation by the FDA and the EMA for the treatments of AS and idiopathic pulmonary fibrosis (IPF).
Pivotal data for Prometic’s intravenous Plasminogen replacement therapy to be presented at American Society for Hematology
Prometic today announced that it will have two presentations at the 59th American Society of Hematology (ASH) Annual Meeting being held Dec. 9-12, 2017 in Atlanta.
Prometic receives clearance from the Swedish Medical Products Agency to initiate plasminogen diabetic foot ulcer phase 2 clinical trial
The Phase 2 clinical trial is a prospective, dose escalation study of the safety, feasibility and initial efficacy of subcutaneous plasminogen for the treatment of DFU in 20 adult subjects.
Prometic receives priority review status from Health Canada for Plasminogen (Ryplazim™)